Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Single Oral Dose (100 mg) Trial to Characterize the Excretion Balance of 14c-radiolabeled BIRB 796 BS and to Determine Its Metabolites in Normal Male Subjects

NCT02211885 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02211885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02211885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Single Oral Dose (100 mg) Trial to Characterize the Excretion Balance of 14c-radiolabeled BIRB 796 BS and to Determine Its Metabolites in Normal Male Subjects
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2002
Completion date
Not reported
Enrollment
6 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy